Prevention of infant eczema by neonatal Bacillus Calmette‐Guérin vaccination: The MIS BAIR randomized controlled trial

• DOI: 10.1111/all.15022
• Publication Date: 2021-07-26T13:55:52Z
• Authors: Laure F. Pittet; Nicole L. Messina; Kaya Gardiner; Bridget Freyne; Veronica Abruzzo; Kate L. Francis; Clare Morrison; Christel Zufferey; Peter Vuillermin; Katrina J. Allen; Anne‐Louise Ponsonby; Roy Robins‐Browne; Frank Shann; Katie L. Flanagan; Rod Phillips; Susan Donath; Dan Casalaz; Nigel Curtis
• Keywords: BCG vaccine

Bacille Calmette-Guérin (BCG) vaccine could play a role in counteracting the rising prevalence of atopic diseases, through its beneficial off-target effects. We aimed to determine whether neonatal BCG vaccination reduces incidence eczema infants.Randomized controlled trial with 1272 infants allocated receive BCG-Denmark or no at birth. The primary outcome was 12-month based on 3-monthly questionnaires. Eczema also assessed clinic visit. ClinicalTrial.gov: NCT01906853.The 32.2% group compared 36.6% control (adjusted risk difference (aRD) -4.3%, 95% CI -9.9% 1.3%, multiple imputation model). In addition, comparing group, 15.7% vs. 19.2% had lesions visit (aRD -3.5%, -8.0% 1.0%); 35.7% 39.0% reported using topical steroids -3.3, -9.2 2.7); and 7.3% 10.2% severe scores -3.0%, -8.8% 2.7%). 344 high-risk (two parents), 35.3% 46.8% -11.5%, -21.9% -1.2%; number needed treat 8.7, 4.6 83.3).There is insufficient evidence recommend all for prevention first year life; however, modest effect observed among infants. A single dose soon after birth reduce two parents.